FORT WORTH, Texas, Sept. 11 /PRNewswire-FirstCall/ -- Wound Management
Technologies, Inc., (OTC Bulletin Board: WNDM), announced today its strategic
plans for the remainder of the year and for 2009. "The company has been
focused on bringing the science and technology to the market for the first 3
quarters of the year to position CellerateRx(TM) as the number one
collagen-based wound care product in the world. We have been working with
several major medical groups, physicians and scientists across the US to
validate our belief that CellerateRx is a 'one-of-a-kind' collagen product,"
stated CEO Scott Haire.
"With our patented technology and the way CellerateRx works when it is
applied to an open wound, we don't believe that there is any other topical
wound care product that can perform as well as CellerateRx," he went on to
say. The company will present the product this week at the New Cardiovascular
Horizons and Management of the Diabetic Foot & Wound Healing (NCVH) conference
in New Orleans, September 10-13.
"This year we wanted to establish ourselves as the leading collagen
product in the $2 billion plus US wound care market by providing science and
evidence-based studies behind CellerateRx.
We believe that these efforts will enable us to strategically grow our
revenue base in 2009."
The company has leveraged its internal relationships and has focused on
the US nursing home market to date. In addition to extended US sales channels,
the company is currently working on leads in international markets with
distributors that have major interest in the CellerateRx product. The
international prevalence of diabetes and its related wounds have spurred sales
interests in both the US and international markets.
About Wound Management Technologies, Inc.:
Wound Management Technologies, Inc. (OTC Bulletin Board: WNDM), with its
corporate headquarters in Fort Worth, Texas, markets and distributes wound
care products to the healthcare market under patented technology licensed to
the Company. The Company is positioned and seeks to be a leading provider of
wound care products. For more information on the Company please visit the
Company's Website at www.Celleraterx.com .
"Safe Harbor" Statement: Under The Private Securities Litigation Reform
Act of 1995: The statements in the press release that relate to the company's
expectations with regard to the future impact on the company's results from
new products in development are "forward-looking statements," within the
meaning of the Private Securities Litigation Reform Act of 1995. Since this
information may contain statements that involve risk and uncertainties and are
subject to change at any time, the company's actual results may differ
materially from expected results. This document may contain forward-looking
statements concerning the Company's operations, current and future performance
and financial condition. These items involve risks and uncertainties such as
product demand, market and customer acceptance, the effect of economic
conditions, competition, pricing, the ability to consummate and integrate
acquisitions, and other risks and uncertainties detailed in the Company's SEC
filings. The Company undertakes no obligation to revise any of these
statements to reflect the future circumstances or the occurrence of
unanticipated events.
For Further Information:
Product Information Shareholder Relations
Cathy Bradshaw Lucy Singleton
President Secretary
954-315-9242 817-820-7080
SOURCE Wound Management Technologies, Inc.
